Currently, the first-generation somatostatin receptor ligands (fg-SRLs), octreotide LAR and
lanreotide autogel, are the mainstays of acromegaly treatment and achieve biochemical …

First-generation somatostatin receptors ligands (SRL) are the mainstay in the medical
treatment of acromegaly, however the percentage of patients controlled with these drugs …

Background Many patients with acromegaly do not achieve biochemical control despite
receiving high doses of the first-generation somatostatin analogues octreotide or lanreotide …

Aim To gather data regarding factors predicting responsiveness to pasireotide in
acromegaly. Patients and methods SSTR2a, SSTR3, SSTR5, AIP, Ki-67 and the adenoma …

Context: Somatostatin receptor subtype 2 (sst2A) protein expression has been demonstrated
to positively correlate with somatostatin analog treatment outcome in GH-secreting …

Acromegaly is a hormonal disorder that arises when the pituitary gland secretes excess
growth hormone (GH), which in turn stimulates a concomitant increase in serum insulin-like …

Acromegaly is a chronic disease with increased morbidity and mortality, where usually
multiple treatment modalities are used. The somatostatin analogs (SSAs) are the mainstay of …

Acromegaly is associated with high morbidity and elevated mortality when not adequately
treated. Surgery is the first-line treatment for most patients as it is the only one that can lead …

Context: Reduced expression of somatostatin receptors (SSTRs) in somatotroph adenomas
and their potential down-regulation after medical treatment may explain the unsatisfactory …

Context Artificial intelligence (AI), in particular machine learning (ML), may be used to
deeply analyze biomarkers of response to first-generation somatostatin receptor ligands (fg …